As we have discussed in previous posts, studies have allegedly shown that the hormones contained in the birth control product NuvaRing® may be linked to various forms of severe side-effects including: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage, myocardial infarction and pulmonary embolism.
As we have also discussed, the first New Jersey trial in the Nuvaring® litigation is scheduled to begin in February 2013. Counsel for Plaintiffs and Defendants have been working tirelessly to prepare the initial ten (10) bellwether cases for trial. To date, Judge Martinotti, who is overseeing all New Jersey state Nuvaring® cases, has refrained from deciding the order of these initial trials. However, at a Case Management Conference on August 8, 2012, Judge Martinotti instructed the parties to meet and confer within the next seven (7) days before providing him with their suggestions. Plaintiffs anticipate that Judge Martinotti will select the first trial in the near future, allowing them to focus their efforts while preparing the strongest possible case against Organon, the manufacturer of Nuvaring®.
If you, or someone you know, has experienced adverse effects as a result of using Nuvaring®, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturer of Nuvaring®.